key: cord-1001782-tteo0nvy
authors: Paley, Michael A; Kim, Alfred H J
title: B cells: more than just for antibodies in SARS-CoV-2 vaccine responses
date: 2021-09-07
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(21)00280-0
sha: 2dbdf498aece29b27857664c1cd1df400e55a15d
doc_id: 1001782
cord_uid: tteo0nvy

nan

The emergence of SARS-CoV-2 has increased the risks of immunosuppressive therapies needed to treat chronic inflammatory diseases, such as glucocorticoids, methotrexate, and B-cell-depleting therapies. 1 Effective vaccines against SARS-CoV-2 provide a central instrument to reduce the risk of severe COVID-19 and death; however, immunosuppressive therapies can blunt vaccine responses. 2 A crucial question, therefore, is which forms of immunosuppression impair vaccine responses, particularly in response to novel platforms such as mRNA-based vaccines.

In a study in The Lancet Rheumatology, Laura Boekel and colleagues 3 measured seroconversion rates against the receptor-binding domain of the SARS-CoV-2 spike protein in 632 patients with autoimmune diseases, including rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, vasculitis, Sjogren's syndrome, and multiple sclerosis, as well as in 289 healthy controls. A key aspect of this study was that investigators measured antibody responses after both the first and the second dose of the vaccine and stratified the analysis by previous SARS-CoV-2 infection. Boekel 4 these data suggest that while methotrexate might blunt the antibody response to a single dose of vaccine, this effect can be overcome by repeated immunisation.

Although reduced antibody responses after B-cell depletion is predictable, what is less well understood is whether T-cell responses would be altered as well. In another study in The Lancet Rheumatology, Matthias Moor and colleagues 5 took a more detailed look at responses to mRNA vaccines against SARS-CoV-2 by examining both T-cell and B-cell responses simultaneously in 96 patients with a treatment history of CD20 B-celldepleting therapies and 29 healthy controls. Similar to Boekel and colleagues, 3 Moor and colleagues 5 found that B-cell-depleting therapy was associated with poor antibody response to the vaccines with a seroconversion rate of 49% (47 of 96 patients) after the second vaccine dose. Additionally, Moor and colleagues found that the rate of T-cell responses to SARS-CoV-2 spike protein, by interferon-γ release assay, were also diminished in the setting of B-cell-depleting therapies compared with healthy controls (20% vs 75%). Thus, B-cell-depleting therapies not only weaken humoral immunity but might also impair cellular immune responses to vaccination.

The association between poor seroconversion and concurrent use of B-cell-depleting therapies seen in both studies has also been observed in other contemporaneous reports. [6] [7] [8] [9] However, what factors predict a poor antibody response have not yet been clarified. To address this knowledge gap, Moor and colleagues measured several laboratory covariates to determine the characteristics associated with optimal antibody responses. The investigators identified four factors that were associated with high antibody titres after immunisation in patients on B-cell-depleting therapies: higher numbers of circulating B cells and CD4 T cells, higher concentrations of IgM, and a longer time since the last infusion of B-cell-depleting agent. By contrast with IgM, circulating concentrations of IgG did not correlate with higher titres of anti-SARS-CoV-2 spike protein after vaccination. Although not a direct measure of the anti-SARS-CoV-2 antibody response, the numbers of circulating B cells and IgM concentration probably serve as an indirect surrogate for the size of the naive B-cell compartment that potentially contains antibodysecreting cells elicited by vaccination. This premise has been reported in a preprint article. 10 Additionally, the number of circulating CD4 T cells likely reflects the potential help that CD4 T cells provide to B cells to optimise antibody responses after vaccination.

The correlation between time since last infusion and antibody titre seen by Moor and colleagues has also been independently observed in patients treated with rituximab, with recovery of seroconversion gradually returning 6 months after the last infusion. 2, 9 By contrast, in a study of patients treated with ocrelizumab, correlation with time since last treatment was not found; however, all patients had received B-celldepleting therapies within 6 months of their SARS-CoV-2 vaccination. 2 Thus, these data raise the possibility that delaying repeat infusions of B-cell-depleting therapies by 6-12 months (when clinically feasible) might facilitate stronger antibody responses after vaccination.

Two previous studies in patients treated with rituximab found that T-cell responses to SARS-CoV-2 vaccination were present regardless of a productive antibody response. 7, 8 Although these results might appear to conflict with the current study results, there was a key methodological difference in the study approaches. The previous studies used an ELISpot assay to assess T-cell responses, which is a highly sensitive assay to measure the number of T cells that recognise a given antigen; whereas Moor and colleagues measured the total amount of interferon-γ released after stimulation, which integrates the number of reactive T cells with the amount of interferon-γ produced per cell. Thus, a reconciliation of both findings suggests the possibility that the number of vaccine-elicited T cells remains unchanged in patients on B-cell-depleting therapies, but that the quality of the T cells in their ability to produce interferon-γ is impaired. This finding highlights a key role of B cells in promoting cellular immunity.

In summary, the collective findings of Boekel and colleagues 3 and Moor and colleagues 5 show the deleterious effect of B-cell-depleting therapies on protective immunity. Whether additional vaccine doses can overcome the detrimental effects of these therapies to generate effective humoral immunity requires further study. 

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry

Effect of Immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Association of naïve B cells with humoral response to SARS-CoV-2 vaccination